Inhibitors of the tyrosine kinase EphB4. Part 4: Discovery and optimization of a benzylic alcohol series

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 8, 2011, Pages 2207-2211

  Barlaam, Bernard ^a   Ducray, Richard ^a   Brempt, Christine Lambert Van Der ^a   Plé, Patrick ^a   Bardelle, Catherine ^a   Brooks, Nigel ^a   Coleman, Tanya ^a   Cross, Darren ^a   Kettle, Jason G ^a   Read, Jon ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Bis anilinopyrimidine; EphB4 kinase; Kinase inhibitor

Indexed keywords

ANILINE DERIVATIVE; BENZYL ALCOHOL DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR;

ANIMAL EXPERIMENT; ARTICLE; DOG; DRUG ACTIVITY; DRUG CLEARANCE; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME INHIBITION; MOUSE; NONHUMAN; RAT;

ADMINISTRATION, ORAL; ANILINE COMPOUNDS; ANIMALS; BENZYL ALCOHOL; BINDING SITES; COMPUTER SIMULATION; CRYSTALLOGRAPHY, X-RAY; DRUG EVALUATION, PRECLINICAL; MICE; MICE, NUDE; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RECEPTOR, EPHB4; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79953273217     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.03.009     Document Type: Article

References (23)

1. For recent reviews see: E.B. Pasquale Nat. Rev. Cancer 10 2010 165
2. N.K. Noren, and E.B. Pasquale Cancer Res. 67 2007 3994
3. N. Kertesz, V. Krasnoperov, R. Reddy, L. Leshanski, S.R. Kumar, S. Zozulya, and P.S. Gill Blood 107 2006 2330
4. V. Krasnoperov, S.R. Kumar, E. Ley, X. Li, J. Scehnet, R. Liu, S. Zozulya, and P.S. Gill Am. J. Pathol. 176 2010 2029
5. Y. Wang, M. Nakayama, M.E. Pitulescu, T.S. Schmidt, M.L. Bochenek, A. Sakakibara, S. Adams, A. Davy, U. Deutsch, U. Luethi, A. Barberis, L.E. Benjamin, T. Maekinen, C.D. Nobes, and R.H. Adams Nature 465 2010 483
6. G. Martiny-Baron, P. Holzer, E. Billy, C. Schnell, J. Brueggen, M. Ferretti, N. Schmiedeberg, J.M. Wood, P. Furet, and P. Imbach Angiogenesis 13 2010 259
7. C. Bardelle, D. Cross, S. Davenport, J.G. Kettle, E.J. Ko, A.G. Leach, A. Mortlock, J. Read, N.J. Roberts, P. Robins, and E.J. Williams Bioorg. Med. Chem. Lett. 18 2008 2776
8. C. Bardelle, T. Coleman, D. Cross, S. Davenport, J.G. Kettle, E.J. Ko, A.G. Leach, A. Mortlock, J. Read, N.J. Roberts, P. Robins, and E.J. Williams Bioorg. Med. Chem. Lett. 18 2008 5717
9. C. Bardelle, B. Barlaam, N. Brooks, T. Coleman, D. Cross, R. Ducray, I. Green, C. Lambert-van der Brempt, A. Olivier, and J. Read Bioorg. Med. Chem. Lett. 20 2010 6242
10. S.A. Mitchell, M.D. Danca, P.A. Blomgren, J.W. Darrow, K.S. Currie, J.E. Kropf, S.H. Lee, S.L. Gallion, J.-M. Xiong, D.A. Pippin, R.W. DeSimone, D.R. Brittelli, D.C. Eustice, A. Bourret, M. Hill-Drzewi, P.M. Maciejewski, and L.L. Elkin Bioorg. Med. Chem. Lett. 19 2009 6991
11. K. Lafleur, D. Huang, T. Zhou, A. Caflisch, and C. Nevado J. Med. Chem. 52 2009 6433
12. Y. Choi, F. Syeda, J.R. Walker, P.J. Finerty, D. Cuerrier, A. Wojciechowski, Q. Liu, S. Dhe-Paganon, and N.S. Gray Bioorg. Med. Chem. Lett. 19 2009 4467
13. See Supplementary data in: M.W. Karaman, S. Herrgard, D.K. Treiber, P. Gallant, C.E. Atteridge, B.T. Campbell, K.W. Chan, P. Ciceri, M.I. Davis, P.T. Edeen, R. Faraoni, M. Floyd, J.P. Hunt, D.J. Lockhart, Z.V. Milanov, M.J. Morrison, G. Pallares, H.K. Patel, S. Pritchard, L.M. Wodicka, and P.P. Zarrinkar Nat. Biotechnol. 26 2008 127
14. The compounds described in reference 8 are also inhibitors of the VEGFR2 and Tie2 receptor tyrosine kinases, both of which are linked to angiogenic mechanisms.
15. The benzodioxole ring is known to produce mechanism based inhibition of P450 enzymes, see: E. Fontana, P.M. Dansette, and S.M. Poli Curr. Drug Met. 6 2005 413
16. PCT international applications WO/2008-104754 (for compd 3-14, 18-32), WO/2008-132505 (for compd 33-34), and WO/2009-010794 (for compd 15-17).
17. 21 and structure factors for the EphB4 complex with compound 32 has been deposited in the Protein Data Bank (2xvd ) together with structure factors and detailed experimental conditions.
18. For a description of this assay see: P.A. Ple, T.P. Green, L.F. Hennequin, J. Curwen, M. Fennell, J. Allen, C. Lambert-van der Brempt, and G. Costello J. Med. Chem. 47 2004 871
19. In addition to ephB4, compound 12 is likely to inhibit other members of the Eph receptors family, given the high structural homology of their kinase domains.
20. Time dependant inhibition (TDI) of CYP450 (isoforms 1A2, 2C9, 2C19, 2D6 and 3A4) was evaluated by pre-incubating the compound (10 μM) with human liver microsomes for 30 min in the presence vs. absence of NADPH, followed by incubation with a specific CYP substrate with NADPH. Compound 12 gave 50% TDI on CYP3A4 with no significant effect on the 4 other isoforms. In the same assay, 1 gave, respectively, 40% and 42% TDI against CYP2C9 and 3A4 and 2 gave 62% TDI against CYP3A4 (see Ref. 7).
21. X. Zhang J. Med. Chem. 51 2008 7099
22. W.L. DeLano The PyMOL Molecular Graphics System 2002 DeLano Scientific San Carlos, CA, USA
23. 2, respectively.